Genes and Genomics

The Genetics Society of Korea (한국유전학회)
권호 표지
DOI QR코드

DOI QR Code

Stimulation of the endosomal TLR pathway enhances autophagy-induced cell death in radiotherapy of breast cancer

  • Kang, Su-Jin (Department of Biological Sciences and Medical & Bio-material Research Center, Kangwon National University) ;
  • Tak, Ji-Hye (Department of Biological Sciences and Medical & Bio-material Research Center, Kangwon National University) ;
  • Cho, Jung-Hyun (Department of Biological Sciences and Medical & Bio-material Research Center, Kangwon National University) ;
  • Lee, Hyo-Ji (Department of Biological Sciences and Medical & Bio-material Research Center, Kangwon National University) ;
  • Jung, Yu-Jin (Department of Biological Sciences and Medical & Bio-material Research Center, Kangwon National University)
  • Received : 2010.10.27
  • Accepted : 2010.11.10
  • Published : 2010.12.30
⟨ Previous Next ⟩

Abstract

Toll-like receptors (TLRs), which are mainly expressed in antigen presenting cells, perform a critical role in innate immunity by recognizing the specific structural patterns of pathogens and transducing signals to induce an inflammatory reaction. Although it has been reported that various solid cancers express endosomal TLRs, TLR3, 7, 8, and 9, the cellular and molecular function of TLRs in tumorigenesis has not yet been elucidated. In this report, we identified the expression of TLR3 and TLR7 in the human breast cancer cell line MCF-7 and found that TLRs stimulated with their specific ligand induced an anti-tumoral effect in this cell line. Among four synthetic commercial agonists of TLR3 and 7, Poly(I:C) and imiquimod (IMQ) proved to have superior anti-tumoral activity over the other agonists. A decreased growth rate was observed in MCF-7 cells treated with either TLR agonist. The decreased growth rate was due to autophagy and autophagy-induced cell death because treatment with 3-methyladenine, inhibitor of autophagy rescued the growth rate and increased the expression levels of autophagy-related genes. Moreover, survival of MCF-7 cells significantly decreased when the cells were stimulated simultaneously with TLR agonists and radiation exposure. Therefore, this study can be applied to developing a therapeutic adjuvant of TLR agonists in radiotherapy for radio-resistant breast cancer treatment.

Keywords

References

  1. Akira S (2006) TLR signaling. Curr. Top. Microbiol .Immunol. 311: 1-16. https://doi.org/10.1007/3-540-32636-7_1
  2. Celis E (2007) Toll-like receptor ligands energize peptide vaccines through multiple paths. Cancer Res. 67: 7945-7947. https://doi.org/10.1158/0008-5472.CAN-07-1652
  3. Choi SS, Chung E and Jung YJ (2010) Newly identified CpG ODNs, M5-30 and M6-395, stimulate mouse immune cells to secrete TNF-alpha and enhance Th1-mediated immunity. J. Microbiol. 48: 512-517. https://doi.org/10.1007/s12275-010-0053-6
  4. Cormary C, Hiver E, Mariame B, Favre G and Tilkin-Mariame AF (2005) Coexpression of CD40L and CD70 by semiallogenic tumor cells induces anti-tumor immunity. Cancer Gene Ther. 12: 963-972. https://doi.org/10.1038/sj.cgt.7700861
  5. Djavaheri-Mergny M, Maiuri MC and Kroemer G (2010) Cross talk between apoptosis and autophagy by caspase-mediated cleavage of Beclin 1. Oncogene 29: 1717-1719. https://doi.org/10.1038/onc.2009.519
  6. Dotti G (2009) Blocking PD-1 in cancer immunotherapy. Blood 114: 1457-1458. https://doi.org/10.1182/blood-2009-05-223412
  7. Egen JG, Kuhns MS and Allison JP (2002) CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 3: 611-618. https://doi.org/10.1038/ni0702-611
  8. Elpek KG, Lacelle C, Singh NP, Yolcu ES and Shirwan H (2007) CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. J. Immunol. 178: 6840-6848. https://doi.org/10.4049/jimmunol.178.11.6840
  9. Flavell RA, Sanjabi S, Wrzesinski SH and Licona-Limon P (2010) The polarization of immune cells in the tumour environment by TGFbeta. Nat. Rev. Immunol. 10: 554-567. https://doi.org/10.1038/nri2808
  10. Gyrd-Hansen M and Meier P (2010) IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat. Rev. Cancer 10: 561-574. https://doi.org/10.1038/nrc2889
  11. Hanada T, Noda NN, Satomi Y, Ichimura Y, Fujioka Y, Takao T, Inagaki F and Ohsumi Y (2007) The Atg12-Atg5 conjugate has a novel E3-like activity for protein lipidation in autophagy. J. Biol. Chem. 282: 37298-37302. https://doi.org/10.1074/jbc.C700195200
  12. Huang B, Zhao J, Unkeless JC, Feng ZH and Xiong H (2008) TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 27: 218-224. https://doi.org/10.1038/sj.onc.1210904
  13. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y and Yoshimori T (2000) LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. Embo J. 19: 5720-5728. https://doi.org/10.1093/emboj/19.21.5720
  14. Krieg AM (2007) Development of TLR9 agonists for cancer therapy. J. Clin. Invest. 117: 1184-1194. https://doi.org/10.1172/JCI31414
  15. Kumar B, Joshi J, Kumar A, Pandey BN, Hazra B and Mishra KP (2007) Radiosensitization by diospyrin diethylether in MCF-7 breast carcinoma cell line. Mol. Cell. Biochem. 304: 287-296. https://doi.org/10.1007/s11010-007-9511-9
  16. Mathew R, Karantza-Wadsworth V and White E (2007) Role of autophagy in cancer. Nat. Rev. Cancer 7: 961-967. https://doi.org/10.1038/nrc2254
  17. Medzhitov R and Janeway C, Jr. (2000a) Innate immune recognition: mechanisms and pathways. Immunol. Rev. 173: 89-97. https://doi.org/10.1034/j.1600-065X.2000.917309.x
  18. Medzhitov R and Janeway C, Jr. (2000b) The Toll receptor family and microbial recognition. Trends Microbiol. 8: 452-456. https://doi.org/10.1016/S0966-842X(00)01845-X
  19. Melief CJ, Van Der Burg SH, Toes RE, Ossendorp F and Offringa R (2002) Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunol. Rev. 188: 177-182. https://doi.org/10.1034/j.1600-065X.2002.18816.x
  20. Mizushima N and Yoshimori T (2007) How to interpret LC3 immunoblotting. Autophagy 3: 542-545. https://doi.org/10.4161/auto.4600
  21. Mougel L, Tarpin M, Albert P, Le Naour R, Devy J, Kaplan H, Venteo L, Carlier A and Madoulet C (2004) Three-dimensional culture and multidrug resistance: effects on immune reactivity of MCF-7 cells by monocytes. Anticancer Res. 24: 935-941.
  22. Peng JC, Hyde C, Pai S, O'Sullivan BJ, Nielsen LK and Thomas R (2006) Monocyte-derived DC primed with TLR agonists secrete IL-12p70 in a CD40-dependent manner under hyperthermic conditions. J. Immunother. 29: 606-615. https://doi.org/10.1097/01.cji.0000211308.82997.4e
  23. Reed JC (2008) Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood 111: 3322-3330. https://doi.org/10.1182/blood-2007-09-078162
  24. Roses RE, Xu M, Koski GK and Czerniecki BJ (2008) Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer. Oncogene 27: 200-207. https://doi.org/10.1038/sj.onc.1210909
  25. Schwartz MJ, Liu H, Hwang DH, Kawamoto H and Scherr DS (2009) Antitumor effects of an imidazoquinoline in renal cell carcinoma. Urology 73: 1156-1162. https://doi.org/10.1016/j.urology.2008.02.010
  26. Smits EL, Ponsaerts P, Berneman ZN and Van Tendeloo VF (2008) The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 13: 859-875. https://doi.org/10.1634/theoncologist.2008-0097
  27. Suzuki N, Suzuki S and Yeh WC (2002) IRAK-4 as the central TIR signaling mediator in innate immunity. Trends Immunol. 23: 503-506. https://doi.org/10.1016/S1471-4906(02)02298-6
  28. Thompson JA, Dissanayake SK, Ksander BR, Knutson KL, Disis ML and Ostrand-Rosenberg S (2006) Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain. Cancer Res. 66: 1147-1154. https://doi.org/10.1158/0008-5472.CAN-05-2289
  29. Tormo D, Checinska A, Alonso-Curbelo D, Perez-Guijarro E, Canon E, Riveiro-Falkenbach E, Calvo TG, Larribere L, Megias D, Mulero F et al. (2009) Targeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in melanoma cells. Cancer Cell 16: 103-114. https://doi.org/10.1016/j.ccr.2009.07.004
  30. Tse K and Horner AA (2007) Update on toll-like receptor-directed therapies for human disease. Ann. Rheum. Dis. 66 Suppl 3: iii77-80.
  31. Vidal D, Matias-Guiu X and Alomar A (2004) Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis. Br. J. Dermatol. 151: 656-662. https://doi.org/10.1111/j.1365-2133.2004.06094.x
  32. Wang R, Wang X, Li B, Lin F, Dong K, Gao P and Zhang HZ (2009) Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo. Breast Cancer Res. Treat. 117: 45-54. https://doi.org/10.1007/s10549-008-0163-6
  33. Wang T, Tamae D, LeBon T, Shively JE, Yen Y and Li JJ (2005) The role of peroxiredoxin II in radiation-resistant MCF-7 breast cancer cells. Cancer Res. 65: 10338-10346. https://doi.org/10.1158/0008-5472.CAN-04-4614
  34. Watts C, West MA and Zaru R (2010) TLR signalling regulated antigen presentation in dendritic cells. Curr. Opin. Immunol. 22: 124-130. https://doi.org/10.1016/j.coi.2009.12.005
  35. Xie Z and Klionsky DJ (2007) Autophagosome formation: core machinery and adaptations. Nat. Cell Biol. 9: 1102-1109. https://doi.org/10.1038/ncb1007-1102
  36. Yi JY, Jung YJ, Choi SS, Hwang J and Chung E (2009) Autophagy-mediated anti-tumoral activity of imiquimod in Caco-2 cells. Biochem. Biophys. Res. Commun. 386: 455-458. https://doi.org/10.1016/j.bbrc.2009.06.046
  37. Zois CE and Koukourakis MI (2009) Radiation-induced autophagy in normal and cancer cells: towards novel cytoprotection and radio- sensitization policies? Autophagy 5: 442-450. https://doi.org/10.4161/auto.5.4.7667

Cited by

  1. IRAK4 and TLR3 Sequence Variants may Alter Breast Cancer Risk among African-American Women vol.4, pp.None, 2010, https://doi.org/10.3389/fimmu.2013.00338
  2. Modes of action of TLR7 agonists in cancer therapy vol.6, pp.10, 2010, https://doi.org/10.2217/imt.14.75
  3. The Early Induction of Suppressor of Cytokine Signaling 1 and the Downregulation of Toll-like Receptors 7 and 9 Induce Tolerance in Costimulated Macrophages vol.38, pp.1, 2010, https://doi.org/10.14348/molcells.2015.2136
  4. The TLR7 agonist imiquimod induces anti-cancer effects via autophagic cell death and enhances anti-tumoral and systemic immunity during radiotherapy for melanoma vol.8, pp.15, 2017, https://doi.org/10.18632/oncotarget.15326
  5. Angiotensin II receptor blockers induce autophagy in prostate cancer cells vol.13, pp.5, 2017, https://doi.org/10.3892/ol.2017.5872
  6. Radio-sensitization of head and neck cancer cells by a combination of poly(I:C) and cisplatin through downregulation of survivin and c-IAP2 vol.42, pp.1, 2010, https://doi.org/10.1007/s13402-018-0403-7
  7. The complement system, toll-like receptors and inflammasomes in host defense: three musketeers’ one target : The CS, TLRs, and Inflammasomes are the first line of immune defense working by cross vol.38, pp.4, 2010, https://doi.org/10.1080/08830185.2019.1609962
  8. Toll‐like receptors: A pathway alluding to cancer control vol.234, pp.12, 2010, https://doi.org/10.1002/jcp.28879
  9. Regulated Necrotic Cell Death in Alternative Tumor Therapeutic Strategies vol.9, pp.12, 2010, https://doi.org/10.3390/cells9122709
  10. Current Strategies for Tumor Photodynamic Therapy Combined With Immunotherapy vol.11, pp.None, 2010, https://doi.org/10.3389/fonc.2021.738323